20.8 C
New York
Wednesday, April 1, 2026

FDA approves vepdegestrant NDA for ESR1-mutated breast cancer


FDA accepts vepdegestrant NDA for ESR1-mutated breast cancer

Related Articles

Stay Connected

0FansLike
0FollowersFollow
0SubscribersSubscribe

Latest Articles